Aquavit Life Sciences comprises two companies, in South Korea and in the United States, providing cGMP manufacturing and research capability to the technologies that carry the Aquavit name.
Built in Korea. Delivered worldwide.
Controlling the making of a device means controlling its quality, and its pace.
The Aquavit manufacturing presence in Korea was established in 2014 and has since expanded, operating under FDA-compliant cGMP practice within ISO-certified quality systems. A second company operates in the United States.
Manufacturing held close rather than at arm's length does more than raise capacity. It lets drugs, biologics and devices be developed in parallel rather than in sequence.
Direct control of quality assurance and quality control, rather than oversight exercised through a contract manufacturer.
Capacity sized for global demand for the device portfolio, with room built in for programs still in development.
Drugs, biologics and devices developed simultaneously rather than sequentially.
FDA-compliant cGMP practice and ISO-certified systems, with CE marking maintained for European market access.
Research capability alongside manufacturing, with access to engineering and life-science talent in both regions.
Manufacturing and research capability held in more than one country, with the resilience that implies.
